Oncology Companion Diagnostic Market Size Will Surpass USD 10.57 Billion By 2032, at 13.2% CAGR Growth: Polaris Market Research

NEW YORK, Jan. 15, 2024 /PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Oncology Companion Diagnostic Market Share, Size, Trends, Industry Analysis Report, By Offering (Product, Services); By Technology; By Disease Type; By End User; By Region; Segment Forecast, 2024- 2032" published by Polaris Market Research in its research repository.

Global oncology companion diagnostic market size and share is predicted to grow from USD 3.45 billion in 2023 to USD 10.57 billion in 2032. It is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 13.3% from 2023 to 2032, according to the latest report by Polaris Market Research.

A Quick Review

• What is Oncology Companion Diagnostic?

As the arena of oncology continues to progress, researchers are allotting sizeable resources in the advancement of not only inventive drug administration but also companion diagnostic to offer selected remedies that preferably serve distinct patients. Companion diagnostic offers information that is crucial for the security and the productive usage of a compatible drug or biological commodity. Companion diagnostic seek to assist healthcare professionals decide if the advantages of a particular therapy exceed probable side effects or risks. The rapidly rising demand for the oncology companion diagnostic market can be attributed to the fact that the requirement for it might be more crucial as cancers are growingly segmented by their molecular attributes and tests become more progressive and can more excellently inspect cancer features.

The oncology companion diagnostic market growth can be attributed to the fact that the potential of it to reinforce pre mature cancer discernment and screening inventiveness is a captivating market driver. Premature diagnosis is vital for enhancing cancer viable figures, rendering these diagnostics important in the battle against the disease. The augmentation of clinical attempts for contemporary cancer care is contributory in pushing the market. These attempts growingly need accurate patient grouping to recognize the most appropriate contenders causing an escalated demand for companion diagnostics.

Request Free Sample Copy of Oncology Companion Diagnostic Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/oncology-companion-diagnostic-market/request-for-sample 

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)

Our Sample Report May Includes:

• 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
• 115+ Pages Research Report (Inclusion of Updated Research).
• Provide Chapter-wise guidance on Request.
• 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends.
• Includes Updated List of table & figures.
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Who are the Leaders in the Diagnostics Market?

• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Biocartis
• Exact Sciences
• Genedrive
• Genomic Health
• Guardant Health
• Illumina
• Invivoscribe
• Myriad Genetics
• QIAGEN
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific

Purchase a Full Detail Report With Complete TOC @ https://www.polarismarketresearch.com/buy/3099/2 

Important Highlights from the Report

• The requirement might be more crucial as cancers are growingly segmented by their molecular attributes and tests become more progressive, thus pushing the market growth.
• The potential of it to reinforce pre-mature cancer discernment and screening inventiveness is a captivating market driver.
• The oncology companion diagnostic market segmentation is primarily based on offering, technology, disease type, end user, and region.
• North America has dominated the market with the largest share in 2022.

Market's Prime Determinants of Growth, Trends, and Opportunities

• Advancement in precision medicine: The worldwide upswing in cancer prevalence stays a foundational driver. The oncology companion diagnostic market size is expanding due to the increasing pervasiveness of several cancer types, highlighting the requirement for progressive diagnostic instruments that sanction accurate patient grouping, improving the probability of a triumphant cure. The speedy advancement in precision medicine, which depends on the tailored cure of patients, functions as a pushing driver. The growing comprehension of the genomic and molecular foundations of cancer encourages the acquisition of companion diagnostics to customize therapies to each patient's distinct profile.
• Growth in selected cancer therapies: The growing obtainability of selected cancer therapies also propels the market. The oncology companion diagnostic market sales are soaring as these therapies frequently deferred by companion diagnostic convey excessively impactful cures while decreasing side effects connected with extensive range perspectives. This, in succession, inspires the demand for companion diagnostics that recognize perfect contenders.

Request for a Discount on this Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/oncology-companion-diagnostic-market/request-for-discount-pricing

Trends and Opportunities

Telemedicine's hastened acquisition endures to play an important part in providing more approachable diagnostic testing and negotiation. Highlighting premature cancer discernment continues as a prime concern with companion diagnostic being influential in this attempt. Escalated research and advancement endeavors have caused inventions in biomarkers and diagnostic tools. The notion of tailored treatment pushed by companion diagnostic acquires propulsion as it illustrates worthier patient results. Governmental conversions persist to rationalize agreement processes while the incorporation of companion diagnostics into telehealth platforms improves patient care.

Segmental Analysis

• Product Segment Witnessed a Sharp Rise

Based on the offering, the product segment witnessed a sharp rise. The oncology companion diagnostic market demand is on the rise as tools and disposables are foundational to the accurate analysis of patient specimens. These instruments circumscribe a gamut of contemporary tools, including automated strainers for immunohistochemistry, PCR appliances for DNA/RNA magnification, NGS platforms for panoramic genomic portrayal, FISH tools for genetic concoction, heaped spectrometers for proteomic analysis, and several mechanized liquid handlers. Flow cytometers, microscopes, and fluorescence readers are important for the inspection of cell analysis. In aligned, consumables circumscribe antibodies, sequencing kits, PCR reagents, embedding substances and FISH exploration. These substances, along with quality regulation specimens, assay plates, and clustering kits, sanction the precise and productive analysis of patient specimens for tailored oncology companion diagnostics.

• The Immunohistochemistry Segment Dominated the Market

Based on technology, the immunohistochemistry segment dominated the market. The oncology companion diagnostic market trends include its foremost part to offer crucial information about patient's tumour issue. IHC locates particular biomarkers within the tissue, helping in the grouping of cancer subtypes and treatment resolution. It contributes to distinguishing tumors into clear-cut subtypes such as hormone receptor-positive breast cancer-leading therapy alternatives. IHC discloses prophetic markers designating the probability of a patient's answer to specific treatments. It also recognizes prediction markers, providing discernment into disease advancement and patient existence.

Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/oncology-companion-diagnostic-market/inquire-before-buying 

(Inquire a report quote OR available discount offers to the sales team before purchase.)

Oncology Companion Diagnostic Market: Report Scope

Regional Insights

North America: This region held the largest oncology companion diagnostic market share due to an upswing in selected therapies, immunotherapies, and the amalgamation of companion diagnostics for patient grouping. Liquid biopsies have acquired distinction as a non-invasive diagnostic procedure. Governmental surveillance from the FDA sanctions the security and productivity of these diagnostics. Alliance between pharmaceutical firms, diagnostics creators, and healthcare organizations has stimulated invention. Constant biomarker-finding endeavors have augmented diagnostics solicitation, and patient consciousness of the vitality of tailored cancer cures has evolved.

Asia Pacific: Companion diagnostics is important in Asia Pacific, especially in nations with progressive healthcare frameworks. The existence of selected cancer therapies frequently backed by companion diagnostics has enhanced treatment results while lessening side effects. Governmental agreements are modernized, improving the safety and efficacy of these diagnostics. Strong clinical attempt ventures, government reinforcement, international alliances, increasing consciousness amongst healthcare professionals and patients, insurance coverage, and an aggressive platform have brought about the industry's augmentation.

Browse the Detail Report "Oncology Companion Diagnostic Market Share, Size, Trends, Industry Analysis Report, By Offering (Product, Services); By Technology; By Disease Type; By End User; By Region; Segment Forecast, 2024- 2032" with in-depth TOC:  https://www.polarismarketresearch.com/industry-analysis/oncology-companion-diagnostic-market               

For Additional Information OR Media Enquiry, Please Mail At: [email protected] 

Key Questions Answered in the Report

• What is the current and expected oncology companion diagnostic market value?

Ans: The current market value is USD 3.90 million, and the expected market value is USD 10.57 billion.

• At what CAGR is the market expected to grow during the forecast period?

Ans: The market is expected to grow at a CAGR of 13.3% during the forecast period.

• Which factors are driving the market growth?

Ans: The factors pushing the market growth are advancement in precision medicine and growth in selected cancer therapies.

• Which segment accounts for the largest oncology companion diagnostic market share?

Ans: Product segment accounted for the largest market share

Polaris Market Research has segmented the Oncology Companion Diagnostic market report based on offering, technology, disease type, end user, and region:

Oncology Companion Diagnostic, Offering Outlook (Revenue - USD Billion, 2019 - 2032)

• Product
• Services

Oncology Companion Diagnostic, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

• Immunohistochemistry
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Others

Oncology Companion Diagnostic, Disease Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Melanoma
• Breast Cancer
• Colorectal Cancer
• Leukaemia
• Prostate Cancer
• Others

Oncology Companion Diagnostic, End User Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospitals
• Diagnostic Labs
• Others

Oncology Companion Diagnostic, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
• Latin America
  • Argentina
  • Brazil
  • Mexico
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Contact:

Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: [email protected]
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | twitter

Logo: https://mma.prnewswire.com/media/1316207/Polaris_Market_Research_Logo.jpg

SOURCE Polaris Market Research